Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Open Access
- 17 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (2), 563-568
- https://doi.org/10.1007/s00262-020-02693-7
Abstract
Immune checkpoint inhibitors (ICIs) are emerging as the new standard of care for treating various metastatic cancers. It is known that effective anti-tumor immune responses are associated with a stronger presence of tumor-infiltrating lymphocytes (TILs) in solid tumor tissue. Cancer patients with relapsing–remitting multiple sclerosis (RRMS) are often under continuous treatment with fingolimod, an immune-modulating drug that inhibits lymphocyte egress from secondary lymphatic organs. Little is known about the effect of fingolimod on ICI cancer therapy, as fingolimod may limit the number of TILs. Here we present three patients with RRMS, who developed various cancers during fingolimod treatment. Histology of all tumors consistently showed low numbers of TILs. A second biopsy taken from one of the tumors, a melanoma, revealed a significant increase of TILs after stopping fingolimod and starting pembrolizumab, indicating a surge in the number and re-invigoration of T cells. Our study suggests that fingolimod limits the number of TILs in solid tumors and may, thus, inhibit anti-cancer immune responses.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_157448)
This publication has 21 references indexed in Scilit:
- FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal ModelMolecular Cancer Therapeutics, 2016
- Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidenceTherapeutic Advances in Neurological Disorders, 2016
- Immunopathology of multiple sclerosisNature Reviews Immunology, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in miceBlood, 2012
- FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1Cancer Research, 2010
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish populationMutation Research, 2006
- FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and MemoryThe Journal of Immunology, 2000